Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Organigram Global's Revenue for the
three
months ended in Mar. 2026 was €37.7 Mil. Organigram Global's average Accounts Receivable for the
three
months ended in Mar. 2026 was €31.5 Mil.
Hence, Organigram Global's Receivables Turnover for the
three
months ended in Mar. 2026 was 1.20.
Organigram Global (STU:0OG) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Organigram Global Receivables Turnover Related Terms
Organigram Global Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Organigram Global's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0OG vs ZTS, UTHR: Receivables Turnover Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organigram Global's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organigram Global Receivables Turnover vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organigram Global's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Organigram Global's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Organigram Global (STU:0OG) has a Receivables Turnover of 1.20 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Organigram Global and its competitors. According to the industry distribution chart, Organigram Global ranks #465 out of 950 companies in the Drug Manufacturers industry, placing it in the top 48.9%.
Is Organigram Global's Receivables Turnover too high?
Organigram Global's current Receivables Turnover is 1.20. The Drug Manufacturers industry median Receivables Turnover is 5.07. Organigram Global's value of 1.20 is 76.3% below this industry median. Based on the distribution chart, Organigram Global ranks #465 out of 950 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Organigram Global has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Organigram Global's Receivables Turnover compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Organigram Global ranks #465 out of 950 companies for Receivables Turnover. This puts Organigram Global in the upper half of its industry. The industry median Receivables Turnover is 5.07. Organigram Global's value of 1.20 is 76.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Drug Manufacturers company?
The median Receivables Turnover among Drug Manufacturers companies is 5.07, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organigram Global's current Receivables Turnover of 1.20 is 76.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Organigram Global and its competitors. For the Drug Manufacturers industry, the median Receivables Turnover is 5.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organigram Global's current Receivables Turnover is 1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organigram Global stock overvalued right now?
Based on GuruFocus' analysis, Organigram Global (STU:0OG) is currently considered Possible Value Trap. The stock's GF Value™ is €1.54, compared to a current price of €0.77 — trading 49.9% below its estimated fair value. The current Receivables Turnover is 1.20 and 76.3% below the Drug Manufacturers industry median of 5.07. Organigram Global's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Organigram Global (STU:0OG), the current Receivables Turnover is 1.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organigram Global (STU:0OG) Overvalued in 2026?
Based on GuruFocus' analysis, Organigram Global stock appears to be undervalued.
The current stock price of €0.77 is trading 49.9% below its estimated GF Value™ of €1.54.
GuruFocus considers Organigram Global to be Possible Value Trap.
Key valuation signals for STU:0OG:
Receivables Turnover: 1.20
GF Value™: €1.54 vs. price of €0.77 (49.9% below fair value)
Industry Position: 76.3% below the Drug Manufacturers median (#465 of 950)
No single metric tells the full story. See the STU:0OG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
60GF Score
Get the complete analysis for STU:0OG
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0OG has been successfully added to your 
